Our scientists are developing technology that combines anti-cancer therapies, including immunotherapy, in a single agent to directly target cancer tumors. This type of agent is capable of greater potency, higher specificity, and less toxicity than the many therapies that can also attack healthy cells.
The thrust of our current efforts is to combine our agents with other immunotherapeutics, such as checkpoint inhibitors, to achieve greater overall response rates and durable responses in patients than are currently observed in the clinic.
Advanced Proteome Therapeutics provides corporate update on multiple activities.
In an Exclusive Interview, the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company’s Technology and R&D Strategy.
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy.
APC Announces Positive Results in Combination Cancer Immunotherapy.
A 4 minute video interview with Dr. Allen Krantz and a visit to the company's lab.Play Video Video
A 10 minute video interview with Dr. Allen Krantz and a visit to the company's lab.Play Video
This website contains historical and forward-looking statements. The forward-looking statements involve risks and uncertainties. Forward looking statements appearing on this website in this presentation represent management's current estimates at the time they were posted and these may change significantly as new information comes to hand. The information contained in this website has been obtained by Advanced Proteome Therapeutics Inc. from its own records and from other sources believed to be reliable, however no representation or warranty is made as to its accuracy or completeness. Reference should be made to the Company's most recent Annual Report filed with Canadian securities regulatory authorities (and available at www.sedar.com) for a description of the major risk factors.